Agios Pharmaceuticals reports Q4 EPS (40c), consensus (34c) Reports Q4 revenue $6.74M, consensus $6.19M. Agios expects to present initial clinical data from the dose escalation portion of the ongoing Phase 1 study of AG-221 at the 2014 American Association for Cancer Research Annual Meeting in early April. Agios expects to continue enrollment in its Phase 1 study of AG-221 and initiate expansion cohorts in late 2014. Agios plans to initiate two Phase 1 clinical trials for AG-120 in early 2014 in patients whose cancers carry an IDH1 mutation. These studies will leverage the clinical trial sites of Agiosí Phase 1 study of AG-221. Agios anticipates initiating single and multiple ascending dose-escalation studies for AG-348 in healthy volunteers in mid-2014. Agios expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements until late 2016.